Vigil Neuroscience Inc (VIGL) Price & Analysis

Compare

404 Followers

VIGL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.31 - $8.10

Previous CloseN/A

Volume101.11K

Average Volume (3M)761.11K

Market Cap

$383.88M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-0.23

Next Earnings

Aug 12, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding47,686,560

10 Day Avg. Volume910,193

30 Day Avg. Volume761,108

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$8.00

Price Target Upside-0.62% Downside

Rating ConsensusHold

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

AcquisitionSanofi's acquisition of Vigil Neuroscience for $8 per share, with an additional $2 contingent on the success of VG-3927, reflects significant valuation and potential upside.

Clinical Trial ResultsInterim data from the Phase 1 clinical study of VG-3927 in healthy volunteers demonstrated a favorable safety and tolerability profile, supporting its further development.

Bears Say

Drug DevelopmentThe discontinuation of the Phase II long-term extension study of iluzanebart may raise concerns about the future development of this compound.

Stock RatingThe stock rating for VIGL has been downgraded to Hold from Buy due to a proposed acquisition by Sanofi.

Vigil Neuroscience Inc News

Vigil Neuroscience Faces Stockholder Demands Post-Merger

Vigil Neuroscience Inc ( ($VIGL) ) has issued an update. On May 21, 2025, Vigil Neuroscience Inc. entered...

5d ago

VIGL

Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger

Vigil Neuroscience Inc ( ($VIGL) ) has shared an announcement. On May 21, 2025, Vigil Neuroscience, Inc. entered...

16d ago

VIGL

Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote

New activity is brewing for Vigil Neuroscience Inc ( ($VIGL) ). The company has submitted a Form DEFM14A...

1M ago

VIGL

Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes

William Blair analyst Myles Minter has maintained their neutral stance on VIGL stock, giving a Hold rating on...

2M ago

VIGL

Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart

Vigil Neuroscience (VIGL) announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal...

2M ago

VIGL

Vigil Neuroscience downgraded to Hold from Buy at Stifel

Stifel downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $11,...

2M ago

VIGL

Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments

Vigil Neuroscience Inc (VIGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

2M ago

VIGL

Vigil Neuroscience downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with a price target of $8, down from...

2M ago

VIGL

Vigil Neuroscience Elects Directors at Annual Meeting

Vigil Neuroscience Inc ( ($VIGL) ) just unveiled an announcement. On May 22, 2025, Vigil Neuroscience, Inc. held...

2M ago

VIGL

Vigil Neuroscience downgraded to Neutral from Outperform at Mizuho

Mizuho downgraded Vigil Neuroscience (VIGL) to Neutral from Outperform with a price target of $8, down from $13,...

2M ago

VIGL

Vigil Neuroscience downgraded to Hold from Buy at Jefferies

Jefferies downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $19,...

2M ago

VIGL

Vigil Neuroscience downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Vigil Neuroscience (VIGL) to Neutral from Outperform with an $8 price target after Sanofi (SNY) agreed...

2M ago

VIGL

Vigil Neuroscience Enters Merger Agreement with Sanofi

Vigil Neuroscience Inc ( ($VIGL) ) has shared an announcement. On May 21, 2025, Vigil Neuroscience, Inc. entered...

2M ago

VIGL

Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Yatin Suneja downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with an $8 price target after...

2M ago

VIGL

VIGL FAQ

What was Vigil Neuroscience Inc’s price range in the past 12 months?

Vigil Neuroscience Inc lowest stock price was $1.31 and its highest was $8.10 in the past 12 months.

What is Vigil Neuroscience Inc’s market cap?

Vigil Neuroscience Inc’s market cap is $383.88M.

When is Vigil Neuroscience Inc’s upcoming earnings report date?

Vigil Neuroscience Inc’s upcoming earnings report date is Aug 12, 2025 which is in 10 days.

How were Vigil Neuroscience Inc’s earnings last quarter?

Currently, no data Available

Is Vigil Neuroscience Inc overvalued?

According to Wall Street analysts Vigil Neuroscience Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vigil Neuroscience Inc pay dividends?

Vigil Neuroscience Inc does not currently pay dividends.

What is Vigil Neuroscience Inc’s EPS estimate?

Vigil Neuroscience Inc’s EPS estimate is -0.42.

How many shares outstanding does Vigil Neuroscience Inc have?

Vigil Neuroscience Inc has 47,686,560 shares outstanding.

What happened to Vigil Neuroscience Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vigil Neuroscience Inc?

Currently, no hedge funds are holding shares in VIGL

Vigil Neuroscience Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-102.70%

Trailing 12-Months

Asset Growth

-14.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vigil Neuroscience Inc

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Vigil Neuroscience Inc (VIGL) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

VIGL Earnings Data >

VIGL Stock 12 Month Forecast

Average Price Target

$8.00

▼(-0.62%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.93,7.935384615384615,7.940769230769231,7.946153846153846,7.951538461538461,7.9569230769230765,7.962307692307692,7.967692307692308,7.973076923076923,7.978461538461539,7.983846153846153,7.989230769230769,7.9946153846153845,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.93,7.935384615384615,7.940769230769231,7.946153846153846,7.951538461538461,7.9569230769230765,7.962307692307692,7.967692307692308,7.973076923076923,7.978461538461539,7.983846153846153,7.989230769230769,7.9946153846153845,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.93,7.935384615384615,7.940769230769231,7.946153846153846,7.951538461538461,7.9569230769230765,7.962307692307692,7.967692307692308,7.973076923076923,7.978461538461539,7.983846153846153,7.989230769230769,7.9946153846153845,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.18,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >